Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
Authors:
- 1 January 2014
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 146 (1) , 110-118.e3
Abstract
No abstract availableKeywords
Funding Information
- AbbVie
This publication has 14 references indexed in Scilit:
- Ulcerative colitisThe Lancet, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2011
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Systematic review: the costs of ulcerative colitis in Western countriesAlimentary Pharmacology & Therapeutics, 2010
- Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or InfliximabGastroenterology, 2009
- Hospitalization for Inflammatory Bowel Disease in the United States Between 1970 and 2004Journal of Clinical Gastroenterology, 2009
- Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM StudyGastroenterology, 2008
- Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitisInflammatory Bowel Diseases, 2007
- Trends in Hospitalization Rates for Inflammatory Bowel Disease in the United StatesClinical Gastroenterology and Hepatology, 2007